Stock Events

Stock Events

Global X S&P 500 U.S. Market Leaders Top 50 

$28.21
56
-$0.36-1.26% 18:30 Today

Statistics

Day High
28.22
Day Low
28.22
52W High
29.02
52W Low
25.57
Volume
325
Avg. Volume
354
Mkt Cap
72.9M
P/E Ratio
-
Dividend Yield
1.98%
Dividend
0.56

Upcoming

Expense Ratio

0.29%
0%
1%+
The annual fee that you pay to the fund company for managing your investment. The lower the expense ratio, the better. This is not an investment recommendation.

Dividends

1.98%Dividend Yield
Jul 26
$0.24
Jan 26
$0.33
Jul 25
$0.53
Mar 20
$2.19
Dec 19
$3.26
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
7.04%

Earnings

17NovExpected
Q3 2022
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-6.88
-4.58
-2.28
0.02
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
2025
0Revenue
-25.58MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FLAG. It's not an investment recommendation.
NVIDIA
8
NVDA
Apple
7
AAPL
Rocket Lab
7
RKLB
Tesla
6
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Brainstorm Cell Therapeutics
BCLI
Mkt Cap11.92M
Brainstorm Cell Therapeutics focuses on developing stem cell therapies for neurodegenerative diseases, similar to Calidi's focus on regenerative medicine.
Stem
STEM
Mkt Cap53.62M
Lineage Cell Therapeutics works on cell-based therapies, directly competing in the regenerative medicine space.
Mesoblast
MESO
Mkt Cap2.25B
Mesoblast Limited specializes in regenerative medicine using mesenchymal lineage cells, aligning closely with Calidi's therapeutic approaches.
Fate Therapeutics
FATE
Mkt Cap297.15M
Fate Therapeutics develops programmed cellular immunotherapies, which competes with Calidi's approach in using biotherapeutics for treatment.
CRISPR Therapeutics
CRSP
Mkt Cap5.39B
CRISPR Therapeutics is involved in gene editing, a cutting-edge technology that can be seen as a competitor to traditional stem cell therapies.
Vericel
VCEL
Mkt Cap2.06B
Vericel Corporation produces autologous cell therapies for treatment of severe diseases, directly competing with Calidi's cell therapy approaches.

Holdings

Regions

Sectors

About

Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
Show more...
CEO
Eric E. Poma
Employees
29
Country
United States
ISIN
US37960A3547

Listings

BOATS
BOATS
CLDI.BOATS
OTC Link
US
CLDWW
ARCX
US
FLAG
XASE
US
CLDI

0 Comments

Share your thoughts

FAQ

What is Global X S&P 500 U.S. Market Leaders Top 50 stock price today?▼
The current price of FLAG is $28.21 USD — it has decreased by -1.26% in the past 24 hours. Watch Global X S&P 500 U.S. Market Leaders Top 50 stock price performance more closely on the chart.
What is Global X S&P 500 U.S. Market Leaders Top 50 stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on ARCX exchange Global X S&P 500 U.S. Market Leaders Top 50 stocks are traded under the ticker FLAG.
Is Global X S&P 500 U.S. Market Leaders Top 50 stock price growing?▼
FLAG stock has fallen by -1.19% compared to the previous week, the month change is a -2.32% fall, over the last year Global X S&P 500 U.S. Market Leaders Top 50 has showed a +3.3% increase.
What is Global X S&P 500 U.S. Market Leaders Top 50 market cap?▼
Today Global X S&P 500 U.S. Market Leaders Top 50 has the market capitalization of 72.9M
When is the next Global X S&P 500 U.S. Market Leaders Top 50 earnings date?▼
Global X S&P 500 U.S. Market Leaders Top 50 is going to release the next earnings report on November 17, 2026.
What were Global X S&P 500 U.S. Market Leaders Top 50 earnings last quarter?▼
FLAG earnings for the last quarter are -2.94 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Global X S&P 500 U.S. Market Leaders Top 50 revenue for the last year?▼
Global X S&P 500 U.S. Market Leaders Top 50 revenue for the last year amounts to 0 USD.
What is Global X S&P 500 U.S. Market Leaders Top 50 net income for the last year?▼
FLAG net income for the last year is -25.58M USD.
Does Global X S&P 500 U.S. Market Leaders Top 50 pay dividends?▼
Yes, FLAG dividends are paid semi-annual. The last dividend per share was 0.24 USD. As of today, Dividend Yield (FWD)% is 1.98%.
How many employees does Global X S&P 500 U.S. Market Leaders Top 50 have?▼
As of September 08, 2026, the company has 29 employees.
In which sector is Global X S&P 500 U.S. Market Leaders Top 50 located?▼
Global X S&P 500 U.S. Market Leaders Top 50 operates in the Health & Wellness sector.
When did Global X S&P 500 U.S. Market Leaders Top 50 complete a stock split?▼
The last stock split for Global X S&P 500 U.S. Market Leaders Top 50 was on August 05, 2025 with a ratio of 1:12.
Where is Global X S&P 500 U.S. Market Leaders Top 50 headquartered?▼
Global X S&P 500 U.S. Market Leaders Top 50 is headquartered in SAN DIEGO, United States.